Optimising preoperative risk stratification tools for prostate cancer using mpMRI

AbstractPurposeTo improve preoperative risk stratification for prostate cancer (PCa) by incorporating multiparametric MRI (mpMRI) features into risk stratification tools for PCa, CAPRA and D’Amico.Methods807 consecutive patients operated on by robot-assisted radical prostatectomy at our institution during the period 2010–2015 were followed to identify biochemical recurrence (BCR). 591 patients were eligible for final analysis. We employed stepwise backward likelihood methodology and penalised Cox cross-validation to identify the most significant predictors of BCR including mpMRI features. mpMRI features were then integrated into image-adjusted (IA) risk prediction models and the two risk prediction tools were then evaluated both with and without image adjustment using receiver operating characteristics, survival and decision curve analyses.Results37 patients suffered BCR. Apparent diffusion coefficient (ADC) and radiological extraprostatic extension (rEPE) from mpMRI were both significant predictors of BCR. Both IA prediction models reallocated more than 20% of intermediate-risk patients to the low-risk group, reducing their estimated cumulative BCR risk from approximately 5% to 1.1%. Both IA models showed improved prognostic performance with a better separation of the survival curves.ConclusionIntegrating ADC and rEPE from mpMRI of the prostate into risk stratification tools improves preoperative risk estimation for BCR.Key points• MRI-derived features, ADC and EPE, improve risk stratification of biochemical recurrence. • Using mpMRI to stratify prostate cancer patients improves the differentiation between risk groups. • Using preoperative mpMRI will help urologists in selecting the most appropriate treatment.

[1]  M. Roethke,et al.  Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. , 2017, European urology.

[2]  H. Hricak,et al.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.

[3]  B. Trock,et al.  3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. , 2008, The Journal of urology.

[4]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[5]  J. Gschwend,et al.  Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy , 2017, The Journal of urology.

[6]  A. Bjartell,et al.  Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. , 2006, European urology.

[7]  R Alagappan,et al.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. , 1997, Radiology.

[8]  M. Cooperberg,et al.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.

[9]  H. Thoeny,et al.  Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI , 2017, European Radiology.

[10]  P. Choyke,et al.  Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy , 2016, PloS one.

[11]  C. Kim,et al.  Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy. , 2014, AJR. American journal of roentgenology.

[12]  R. Tibshirani,et al.  Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .

[13]  B. Seo,et al.  Additional value of diffusion-weighted imaging to evaluate multifocal and multicentric breast cancer detected using pre-operative breast MRI , 2017, European Radiology.

[14]  Y. Huan,et al.  A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer , 2017, European Radiology.

[15]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[16]  H. Heinzer,et al.  Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models. , 2016, European urology.

[17]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[18]  Henrik S. Thomsen,et al.  Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology , 2015, European Radiology.

[19]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[20]  E. Klein,et al.  Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. , 2009, European urology.

[21]  N. Cho,et al.  Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results , 2016, European Radiology.

[22]  J. Cho,et al.  Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging , 2017, Investigative and clinical urology.

[23]  M. Gönen,et al.  Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters , 2016, European Radiology.

[24]  Nicola Schieda,et al.  Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer. , 2016, AJR. American journal of roentgenology.

[25]  M. Menon,et al.  Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. , 2010, European urology.

[26]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[27]  Yu-Dong Zhang,et al.  MR‐based prognostic nomogram for prostate cancer after radical prostatectomy , 2017, Journal of magnetic resonance imaging : JMRI.

[28]  Martin Biermann,et al.  A simple versatile solution for collecting multidimensional clinical data based on the CakePHP web application framework , 2014, Comput. Methods Programs Biomed..

[29]  H. Akaike A new look at the statistical model identification , 1974 .

[30]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[31]  H. Huisman,et al.  1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy , 2015, Acta Radiologica.

[32]  A. Haese*,et al.  External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. , 2015, The Journal of urology.

[33]  U. Studer,et al.  The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. , 2008, European urology.

[34]  A. Paul,et al.  Do prostate cancer nomograms give accurate information when applied to European patients? , 2015, Scandinavian journal of urology.

[35]  A. Vickers,et al.  Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. , 2016, European urology.

[36]  M. Kattan,et al.  Management of prostate‐specific antigen relapse in prostate cancer: A European consensus , 2004, International journal of clinical practice.

[37]  Shyam Natarajan,et al.  Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsies , 2016, Cancer.

[38]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[39]  Jeong Yeon Cho,et al.  PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer , 2016, European Radiology.

[40]  I. Coman,et al.  Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy , 2016, Medicine.